Molecular Partners Ag (MOLN) Change in Accured Expenses (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Change in Accured Expenses of -$3050.8 for Q1 2026, down 16.27% year-on-year from -$3643.7 in Q1 2025, and up 99.88% on a QoQ basis from -$2.5 million in Q3 2025.
Molecular Partners Ag (MOLN) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Change in Accured Expenses for 6 consecutive years, with -$3050.8 the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -3,050.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,050.76 |
| Mar 31, 2026 | -3,050.76 |
| Sep 30, 2025 | -2.49 Mn |
| Sep 30, 2025 | -2.49 Mn |
| Jun 30, 2025 | 2.41 Mn |
| Jun 30, 2025 | 2.41 Mn |
| Mar 31, 2025 | -2,623.80 |
| Mar 31, 2025 | -2,623.80 |
| Sep 30, 2024 | 971,024.17 |
| Sep 30, 2024 | 971,024.17 |
| Jun 30, 2024 | -929,315.48 |
| Jun 30, 2024 | -929,315.48 |
| Mar 31, 2024 | -1,826.22 |
| Mar 31, 2024 | -1,826.22 |
| Sep 30, 2023 | 1.82 Mn |
| Sep 30, 2023 | 1.82 Mn |
| Jun 30, 2023 | -1.79 Mn |
| Jun 30, 2023 | -1.79 Mn |
| Mar 31, 2023 | -2,852.11 |
| Mar 31, 2023 | -2,852.11 |